🔗 Share this article

The first new treatments for gonorrhoea in a generation are being viewed as a "significant breakthrough" in the fight against drug-resistant strains of the pathogen, according to researchers.

A Global Health Concern

Gonorrhoea infections are on the rise around the world, with figures suggesting more than 82 million new cases each year. Notably increased rates are reported in Africa and countries within the World Health Organization's Western Pacific region, which spans from Mongolia and China to New Zealand. In England, cases have reached a all-time high, while rates across Europe in 2023 were three times higher compared to those in 2014.

“The clearance of fresh medications for gonorrhoea is an important and timely development in the face of growing infection rates, increasing antimicrobial resistance and the very limited therapeutic options currently available.”

Health officials are particularly alarmed about the increase in antibiotic-resistant strains. The global health body has designated it as a "critical concern". Ongoing monitoring showed that resistance to key first-line drugs like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

A Pair of Novel Drugs Secure Clearance

Zoliflodacin, also known as Nuzolvence, was authorized by the US Food and Drug Administration in December for combating gonorrhoea. This STI can lead to significant complications, including the inability to conceive. Researchers anticipate that focused deployment of this new drug will help slow the development of resistance.

Gepotidacin, developed by the pharmaceutical company GlaxoSmithKline, gained clearance in concurrent days. This treatment, which is employed against UTIs, was shown in trials to be effective against drug-resistant strains of the gonorrhoea bacteria.

An Innovative Development Model

This new treatment was the result of a innovative non-profit model for medication research. The charitable organization Global Antibiotic Research & Development Partnership collaborated with the drug firm Innoviva to see it through.

“This milestone represents a significant shift in the treatment of superbug gonorrhoea, which previously has been outpacing our drug pipeline.”

Research Study Data and Global Access

According to findings detailed in a major medical journal, the new drug cured over nine in ten of genital gonorrhoea infections. This establishes an comparable level with the typical regimen, which uses an injection and a pill. The trial involved hundreds of patients from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its unique model, GARDP has the authority to license and sell the drug in a wide range of developing nations.

Medical professionals treating patients have expressed hope. Access to a single-dose, oral treatment such as this is described as a "revolutionary step" for public health efforts. This is considered vital to reduce the burden of the infection for patients and to halt the transmission of highly drug-resistant gonorrhoea around the world.